Page last updated: 2024-12-10

sch 23390

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SCH 23390: a selective D1-receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

SCH 23390 : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 7 and a hydroxy substituent at position 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3036864
CHEMBL ID62
CHEBI ID92798
SCHEMBL ID2916216
MeSH IDM0528880

Synonyms (44)

Synonym
BRD-K45435259-001-01-6
1h-3-benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-, (r)-
sch-23390
2,3,4,5-tetrahydro-8-chloro-3-methyl-5-phenyl-1h-3-benzazepin-7-ol (r)-
1h-3-benzazepin-7-ol, 2,3,4,5-tetrahydro-8-chloro-3-methyl-5-phenyl-, (r)-
tocris-0925
NCGC00024877-01
sch 23388
87075-17-0
(r)-2,3,4,5-tetrahydro-8-chloro-3-methyl-5-phenyl-1h-3-benzazepin-7-ol
PDSP2_001507
LOPAC0_000456
BIOMOL-NT_000016
PDSP1_001523
PDSP1_000615
BPBIO1_001173
sch 23390
PDSP2_000612
NCGC00024877-03
NCGC00024877-02
NCGC00024877-04
sch23390
CHEMBL62 ,
(5r)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
unii-ugt5535req
ugt5535req ,
CCG-204548
sch 23390,r(+)
cas_87134-87-0
8-chloro-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepin-7-ol(sch 23390)
bdbm82247
sch 23390 (r-enantiomer)
1h-3-benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-, (5r)-
r-(+)-sch 23390
SCHEMBL2916216
CHEBI:92798
r-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine
GOTMKOSCLKVOGG-OAHLLOKOSA-N ,
DTXSID40873376
r-(+)-sch-23390
BRD-K45435259-003-03-8
SDCCGSBI-0050441.P002
NCGC00024877-09
(r)-8-chloro-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepin-7-ol

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with SCH 23390 modestly attenuated the methamphetamine discrimination suggesting that the D1 receptor subtype may be involved in the discriminative stimulus effects of methamphetamine."( Pavlovian discriminative stimulus effects of methamphetamine in male Japanese quail (Coturnix japonica).
Akins, CK; Levi Bolin, B; Singleton, DL, 2014
)
0.73

Toxicity

ExcerptReferenceRelevance
" To examine the roles of each of these proteins in methylone-induced toxic effects, we used SERT and DAT knockout (KO) mice and assessed the hyperthermic and lethal effects caused by a single administration of methylone."( Methylone-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters.
Goda, Y; Hall, FS; Ito, M; Kikura-Hanajiri, R; Lesch, KP; Moriya, Y; Murphy, DL; Ohara, A; Piao, YS; Sora, I; Uhl, GR, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" Compared to 2, these heterocyclic phenol isosteres showed much better pharmacokinetic profiles as demonstrated by rat plasma levels."( Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
Burnett, DA; Favreau, L; Fawzi, A; Greenlee, WJ; Lachowicz, JE; Smith, M; Spring, R; Wu, WL; Zhang, H, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
" GHB is frequently combined with other recreational drugs although these interactions are not well characterised."( Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry.
McGregor, IS; van Nieuwenhuijzen, PS, 2009
)
0.35
"This study investigated whether ethanol combined with low doses of morphine produces rewarding effects in rats."( Rewarding effects of ethanol combined with low doses of morphine through dopamine D1 receptors.
Ise, Y; Katayama, S; Mori, T; Nagase, H; Suzuki, T, 2013
)
0.39
"The aim of this study was to explore effects on anxiety-like behavior of D1 dopamine receptor agonist, SKF-38393, and of D1 dopamine receptor antagonist, SCH-23390, given alone or in combination with a low dose of 17β-estradiol (17β-E2) to ovariectomized (OVX) rats."( Effects of SCH-23390 in combination with a low dose of 17β-estradiol on anxiety-like behavior in ovariectomized rats.
Fedotova, J, 2014
)
0.4
"This report compares the effects on medial forebrain bundle self-stimulation of injecting into either the sublenticular central extended amygdala (SLEAc) or nucleus accumbens shell (NAcS) the D1 dopamine receptor blocker SCH23390 or the D2 dopamine receptor agonist quinpirole alone or in combination with the AMPA glutamate receptor blocker NBQX."( Comparison of the effects on brain stimulation reward of D1 blockade or D2 stimulation combined with AMPA blockade in the extended amygdala and nucleus accumbens.
Kuehn, L; Schmid, E; Stoehr, M; Waraczynski, M; Zwifelhofer, W, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
"02 mg/kg, subcutaneous), on MDMA self-administration, effects of this dose range on the MA dose-response curve were determined."( Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats.
Brennan, KA; Carati, C; Fitzmaurice, PS; Lea, RA; Schenk, S, 2009
)
0.35
" The AMPH-suppressed SIP manifested again following 5-days of pretreatment with a sub-threshold dosage of AMPH (1."( Role of dopaminergic DAD1 and DAD2 receptors in the sensitization of amphetamine-suppressed schedule-induced polydipsia in rats.
Lin, PJ; Liu, YP; Tseng, CJ; Tung, CS; Wan, FJ, 2009
)
0.35
"5 mg/kg), an average tissue concentration of approximately 60 nM was detected compared to 15 nM when the drug was dosed at 2 mg/kg, indicating a linear response between dose and detected abundance."( Qualitative and quantitative MALDI imaging of the positron emission tomography ligands raclopride (a D2 dopamine antagonist) and SCH 23390 (a D1 dopamine antagonist) in rat brain tissue sections using a solvent-free dry matrix application method.
Andren, PE; Farde, L; Goodwin, RJ; Harrison, DJ; Iverson, SL; Mackay, CL; Nilsson, A, 2011
)
0.57
" After bilaterally implantation of cannulae into the CA1 and/or VTA in adult male Wistar rats weighing 210-310 g, dose-response effects of different doses of intra-VTA morphine (0."( Role of D1/D2 dopamine receptors in the CA1 region of the rat hippocampus in the rewarding effects of morphine administered into the ventral tegmental area.
Esmaeili, MH; Haghparast, A; Kermani, M; Parvishan, A, 2012
)
0.38
" This study examined the dose-response relationship of the selective D(1) agonist, SKF38393 (0."( D(1) receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats.
Adelekun, AE; Hannaway, KE; Horiguchi, M; Huang, M; Jayathilake, K; Meltzer, HY, 2013
)
0.39
" We then performed a dose-response study to test for chloro-APB-induced restoration of righting during continuous isoflurane anesthesia."( Activation of D1 dopamine receptors induces emergence from isoflurane general anesthesia.
Brown, EN; Chemali, JJ; Solt, K; Taylor, NE, 2013
)
0.39
" We treated adolescent, male rats with olanzapine (Ola) on post-natal days 28-49, under dosing conditions that approximate those employed therapeutically in humans."( Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.
Bailey, AM; Burke, JS; Cheer, JF; Elnabawi, A; Frost, DO; Kallevang, JK; Kolb, B; Lansink, CS; Merchenthaler, I; Milstein, JA; Turek, KC; Vinish, M, 2013
)
0.39
" A second study showed inverted-U shaped dose-response effects of the agonist, such that low levels of sexually motivated song were observed at low and high levels of D1 receptor activation."( Inverted-U shaped effects of D1 dopamine receptor stimulation in the medial preoptic nucleus on sexually motivated song in male European starlings.
Kelm-Nelson, CA; Pawlisch, BA; Riters, LV; Stevenson, SA, 2014
)
0.4
" Exposure to amisulpride (D2/3 receptor antagonist) induced a biphasic dose-response in total distance travelled and in angular velocity."( Differential effects of dopamine D1 and D 2/3 receptor antagonism on motor responses.
Gerlai, R; Muraleetharan, A; Nowicki, M; Tran, S, 2015
)
0.42
" Expression levels of Arc and Fos mRNA in the hippocampus and amygdala were also evaluated on the second day of dosing by fluorescent in situ hybridization (FISH) and reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)."( Gene expression analysis of Arc mRNA as a neuronal cell activity marker in the hippocampus and amygdala in two-way active avoidance test in rats.
Igarashi, I; Iguchi, T; Kai, K; Mori, K; Takahashi, E; Tsuchiya, Y; Yasuno, K,
)
0.13
" Consequences on rat horizontal locomotion and behavior of acute, intermittent (once daily dosing over 10 days), and binge (three-time daily dosing for 3 days) MDPV administration as well as challenge after 10 day MDPV withdrawal were studied."( Acute and chronic neurobehavioral effects of the designer drug and bath salt constituent 3,4-methylenedioxypyrovalerone in the rat.
Atehortua-Martinez, LA; Benturquia, N; Callebert, J; Campolongo, P; Chasseigneaux, S; Chen, H; Etheve-Quelquejeu, M; Laplanche, JL; Mai, A; Masniere, C; Mégarbane, B; Zwergel, C, 2019
)
0.51
" Importantly, the dose-response curve for this action was right-shifted relative to working memory, as seen with systemic administration."( Receptor and circuit mechanisms underlying differential procognitive actions of psychostimulants.
Berridge, CW; Spencer, RC, 2019
)
0.51
" Both Sch 23390 and haloperidol attenuated the discrimination of low MDPV doses and essentially shifted the dose-response curve to the right but failed to block discrimination of the training dose."( Characterization of 3,4-methylenedioxypyrovalerone discrimination in female Sprague-Dawley rats.
Baker, LE; Cargile, KJ; Lunn, JA; Thomas, AM, 2021
)
1.1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzazepineA group of two-ring heterocyclic compounds consisting of a benzene ring fused to an azepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency56.23410.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886
dopamine D1 receptorHomo sapiens (human)Potency0.00370.00521.30228.1995AID624455
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
USP1 protein, partialHomo sapiens (human)Potency19.95260.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency3.54810.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency23.25030.000811.382244.6684AID686978; AID686979
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.11890.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency14.83650.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.67020.035520.977089.1251AID504332
beta-2 adrenergic receptorHomo sapiens (human)Potency29.09290.00586.026332.6427AID485366
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency19.95260.00207.533739.8107AID891
D(1A) dopamine receptorHomo sapiens (human)Potency792.45230.02245.944922.3872AID488982; AID488983
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenylate cyclase type 6Homo sapiens (human)Ki0.00130.00130.00130.0013AID34289
Adenylate cyclase type 3 Homo sapiens (human)Ki0.00130.00130.00130.0013AID34289
Adenylate cyclase type 9Homo sapiens (human)Ki0.00130.00130.00130.0013AID34289
Adenylate cyclase type 5Homo sapiens (human)Ki0.00130.00130.00130.0013AID34289
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.01300.00020.667710.0000AID5241
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)1.04050.00000.74728.0000AID1409500; AID1542813
D(2) dopamine receptorHomo sapiens (human)Ki0.94560.00000.651810.0000AID458498; AID63999
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.01300.00010.601710.0000AID5241
DRattus norvegicus (Norway rat)IC50 (µMol)0.00100.00030.50267.7625AID61181; AID61197; AID63370
DRattus norvegicus (Norway rat)Ki0.00040.00010.610010.0000AID61498; AID61503; AID61513; AID61519; AID61526; AID61651; AID61673
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.76800.00010.25675.8000AID65625
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)0.04610.00031.84739.2250AID1542812; AID1547946; AID1547950; AID255273; AID340241; AID346412; AID566248; AID673208; AID673216; AID751687
D(1A) dopamine receptorHomo sapiens (human)Ki0.00240.00010.836310.0000AID1242914; AID1664374; AID343743; AID346412; AID458496; AID611929; AID61822; AID61825; AID61830; AID63207; AID673208; AID751687
D(1B) dopamine receptorHomo sapiens (human)IC50 (µMol)0.00110.00061.15468.0000AID346416
D(1B) dopamine receptorHomo sapiens (human)Ki0.00290.00030.40177.9000AID1664375; AID239294; AID346416; AID458497
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.01300.00020.590910.0000AID5241
D(1) dopamine receptorCarassius auratus (goldfish)Ki0.00130.00130.00130.0013AID34289
Adenylate cyclase type 8Homo sapiens (human)Ki0.00130.00130.00130.0013AID34289
D(1A) dopamine receptorSus scrofa (pig)Ki0.00050.00051.22238.8000AID272392
Adenylate cyclase type 7Homo sapiens (human)Ki0.00130.00130.00130.0013AID34289
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)5.00030.00010.54948.4000AID61197; AID64282; AID64424
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.62460.00000.437510.0000AID63803; AID63822; AID65092; AID65257; AID65429; AID65718
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)Ki0.00810.00000.73078.0000AID239294
Adenylate cyclase type 2Homo sapiens (human)Ki0.00130.00130.00130.0013AID34289
Adenylate cyclase type 1Homo sapiens (human)Ki0.00130.00130.00130.0013AID34289
DMus musculus (house mouse)Ki0.00040.00040.76232.5300AID61843
Adenylate cyclase type 4Homo sapiens (human)Ki0.00130.00130.00130.0013AID34289
DBos taurus (cattle)Ki0.01380.00012.367610.0000AID63050; AID63051
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.38910.00030.70285.3660AID203852
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)K 0.50.00040.00040.00420.0062AID61343
DRattus norvegicus (Norway rat)K0.50.00040.00030.01430.1490AID61347; AID61349; AID61353
Histamine H2 receptorCavia porcellus (domestic guinea pig)K0.50.10100.00010.40364.8000AID88009
D(2) dopamine receptorRattus norvegicus (Norway rat)K0.50.50000.00090.02480.0581AID64783
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (192)

Processvia Protein(s)Taxonomy
renal water homeostasisAdenylate cyclase type 6Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 6Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 6Homo sapiens (human)
dopamine receptor signaling pathwayAdenylate cyclase type 6Homo sapiens (human)
negative regulation of neuron projection developmentAdenylate cyclase type 6Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 6Homo sapiens (human)
negative regulation of urine volumeAdenylate cyclase type 6Homo sapiens (human)
cellular response to prostaglandin E stimulusAdenylate cyclase type 6Homo sapiens (human)
cellular response to catecholamine stimulusAdenylate cyclase type 6Homo sapiens (human)
blood vessel diameter maintenanceAdenylate cyclase type 6Homo sapiens (human)
cellular response to vasopressinAdenylate cyclase type 6Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 6Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 6Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 3 Homo sapiens (human)
signal transductionAdenylate cyclase type 3 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 3 Homo sapiens (human)
single fertilizationAdenylate cyclase type 3 Homo sapiens (human)
acrosome reactionAdenylate cyclase type 3 Homo sapiens (human)
sensory perception of smellAdenylate cyclase type 3 Homo sapiens (human)
olfactory learningAdenylate cyclase type 3 Homo sapiens (human)
flagellated sperm motilityAdenylate cyclase type 3 Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 3 Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 3 Homo sapiens (human)
in utero embryonic developmentAdenylate cyclase type 9Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 9Homo sapiens (human)
signal transductionAdenylate cyclase type 9Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 9Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 9Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAdenylate cyclase type 9Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAdenylate cyclase type 5Homo sapiens (human)
locomotory behaviorAdenylate cyclase type 5Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 5Homo sapiens (human)
neuromuscular process controlling balanceAdenylate cyclase type 5Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusAdenylate cyclase type 5Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1B) dopamine receptorHomo sapiens (human)
response to amphetamineD(1B) dopamine receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinD(1B) dopamine receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureD(1B) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(1B) dopamine receptorHomo sapiens (human)
associative learningD(1B) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1B) dopamine receptorHomo sapiens (human)
negative regulation of NAD(P)H oxidase activityD(1B) dopamine receptorHomo sapiens (human)
wound healingD(1B) dopamine receptorHomo sapiens (human)
response to cocaineD(1B) dopamine receptorHomo sapiens (human)
positive regulation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(1B) dopamine receptorHomo sapiens (human)
regulation of female receptivityD(1B) dopamine receptorHomo sapiens (human)
sensitizationD(1B) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1B) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1B) dopamine receptorHomo sapiens (human)
reactive oxygen species metabolic processD(1B) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
signal transductionAdenylate cyclase type 8Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAdenylate cyclase type 8Homo sapiens (human)
learning or memoryAdenylate cyclase type 8Homo sapiens (human)
memoryAdenylate cyclase type 8Homo sapiens (human)
long-term memoryAdenylate cyclase type 8Homo sapiens (human)
locomotory behaviorAdenylate cyclase type 8Homo sapiens (human)
glucose mediated signaling pathwayAdenylate cyclase type 8Homo sapiens (human)
positive regulation of synaptic plasticityAdenylate cyclase type 8Homo sapiens (human)
positive regulation of CREB transcription factor activityAdenylate cyclase type 8Homo sapiens (human)
activation of protein kinase A activityAdenylate cyclase type 8Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 8Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusAdenylate cyclase type 8Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwayAdenylate cyclase type 8Homo sapiens (human)
glucose homeostasisAdenylate cyclase type 8Homo sapiens (human)
regulation of insulin secretionAdenylate cyclase type 8Homo sapiens (human)
protein complex oligomerizationAdenylate cyclase type 8Homo sapiens (human)
protein homooligomerizationAdenylate cyclase type 8Homo sapiens (human)
regulation of cytosolic calcium ion concentrationAdenylate cyclase type 8Homo sapiens (human)
cellular response to calcium ionAdenylate cyclase type 8Homo sapiens (human)
cellular response to morphineAdenylate cyclase type 8Homo sapiens (human)
cellular response to glucose stimulusAdenylate cyclase type 8Homo sapiens (human)
cellular response to glucagon stimulusAdenylate cyclase type 8Homo sapiens (human)
regulation of cellular response to stressAdenylate cyclase type 8Homo sapiens (human)
neuroinflammatory responseAdenylate cyclase type 8Homo sapiens (human)
positive regulation of long-term synaptic potentiationAdenylate cyclase type 8Homo sapiens (human)
positive regulation of long-term synaptic depressionAdenylate cyclase type 8Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 8Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 8Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 8Homo sapiens (human)
regulation of adaptive immune responseAdenylate cyclase type 7Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 7Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 7Homo sapiens (human)
maternal process involved in female pregnancyAdenylate cyclase type 7Homo sapiens (human)
cellular response to lithium ionAdenylate cyclase type 7Homo sapiens (human)
cellular response to ethanolAdenylate cyclase type 7Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseAdenylate cyclase type 7Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 7Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 7Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 2Homo sapiens (human)
cAMP-mediated signalingAdenylate cyclase type 2Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 2Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 1Homo sapiens (human)
axonogenesisAdenylate cyclase type 1Homo sapiens (human)
long-term memoryAdenylate cyclase type 1Homo sapiens (human)
circadian rhythmAdenylate cyclase type 1Homo sapiens (human)
response to xenobiotic stimulusAdenylate cyclase type 1Homo sapiens (human)
cAMP-mediated signalingAdenylate cyclase type 1Homo sapiens (human)
positive regulation of CREB transcription factor activityAdenylate cyclase type 1Homo sapiens (human)
regulation of circadian rhythmAdenylate cyclase type 1Homo sapiens (human)
cellular response to calcium ionAdenylate cyclase type 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenylate cyclase type 1Homo sapiens (human)
neuroinflammatory responseAdenylate cyclase type 1Homo sapiens (human)
positive regulation of long-term synaptic potentiationAdenylate cyclase type 1Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 1Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 4Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenylate cyclase type 4Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 4Homo sapiens (human)
synaptic transmission, dopaminergicDBos taurus (cattle)
vasodilationDBos taurus (cattle)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
adenylate cyclase activityAdenylate cyclase type 6Homo sapiens (human)
protein kinase C bindingAdenylate cyclase type 6Homo sapiens (human)
protein bindingAdenylate cyclase type 6Homo sapiens (human)
ATP bindingAdenylate cyclase type 6Homo sapiens (human)
protein kinase bindingAdenylate cyclase type 6Homo sapiens (human)
metal ion bindingAdenylate cyclase type 6Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 3 Homo sapiens (human)
calmodulin bindingAdenylate cyclase type 3 Homo sapiens (human)
ATP bindingAdenylate cyclase type 3 Homo sapiens (human)
metal ion bindingAdenylate cyclase type 3 Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 9Homo sapiens (human)
ATP bindingAdenylate cyclase type 9Homo sapiens (human)
metal ion bindingAdenylate cyclase type 9Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 5Homo sapiens (human)
ATP bindingAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase bindingAdenylate cyclase type 5Homo sapiens (human)
metal ion bindingAdenylate cyclase type 5Homo sapiens (human)
scaffold protein bindingAdenylate cyclase type 5Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1B) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1B) dopamine receptorHomo sapiens (human)
protein bindingD(1B) dopamine receptorHomo sapiens (human)
dopamine bindingD(1B) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1B) dopamine receptorHomo sapiens (human)
actin bindingAdenylate cyclase type 8Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 8Homo sapiens (human)
calmodulin bindingAdenylate cyclase type 8Homo sapiens (human)
ATP bindingAdenylate cyclase type 8Homo sapiens (human)
calcium- and calmodulin-responsive adenylate cyclase activityAdenylate cyclase type 8Homo sapiens (human)
protein homodimerization activityAdenylate cyclase type 8Homo sapiens (human)
metal ion bindingAdenylate cyclase type 8Homo sapiens (human)
protein heterodimerization activityAdenylate cyclase type 8Homo sapiens (human)
protein dimerization activityAdenylate cyclase type 8Homo sapiens (human)
protein phosphatase 2A bindingAdenylate cyclase type 8Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 7Homo sapiens (human)
ATP bindingAdenylate cyclase type 7Homo sapiens (human)
metal ion bindingAdenylate cyclase type 7Homo sapiens (human)
magnesium ion bindingAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 2Homo sapiens (human)
ATP bindingAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase bindingAdenylate cyclase type 2Homo sapiens (human)
manganese ion bindingAdenylate cyclase type 2Homo sapiens (human)
calmodulin bindingAdenylate cyclase type 1Homo sapiens (human)
ATP bindingAdenylate cyclase type 1Homo sapiens (human)
calcium- and calmodulin-responsive adenylate cyclase activityAdenylate cyclase type 1Homo sapiens (human)
metal ion bindingAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 4Homo sapiens (human)
protein kinase C bindingAdenylate cyclase type 4Homo sapiens (human)
protein bindingAdenylate cyclase type 4Homo sapiens (human)
ATP bindingAdenylate cyclase type 4Homo sapiens (human)
metal ion bindingAdenylate cyclase type 4Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (55)

Processvia Protein(s)Taxonomy
plasma membraneAdenylate cyclase type 6Homo sapiens (human)
ciliumAdenylate cyclase type 6Homo sapiens (human)
membraneAdenylate cyclase type 6Homo sapiens (human)
stereociliumAdenylate cyclase type 6Homo sapiens (human)
plasma membraneAdenylate cyclase type 6Homo sapiens (human)
cytoplasmAdenylate cyclase type 3 Homo sapiens (human)
Golgi apparatusAdenylate cyclase type 3 Homo sapiens (human)
plasma membraneAdenylate cyclase type 3 Homo sapiens (human)
ciliumAdenylate cyclase type 3 Homo sapiens (human)
membraneAdenylate cyclase type 3 Homo sapiens (human)
ciliary membraneAdenylate cyclase type 3 Homo sapiens (human)
plasma membraneAdenylate cyclase type 3 Homo sapiens (human)
cytosolAdenylate cyclase type 9Homo sapiens (human)
plasma membraneAdenylate cyclase type 9Homo sapiens (human)
membraneAdenylate cyclase type 9Homo sapiens (human)
axonAdenylate cyclase type 9Homo sapiens (human)
dendriteAdenylate cyclase type 9Homo sapiens (human)
plasma membraneAdenylate cyclase type 9Homo sapiens (human)
plasma membraneAdenylate cyclase type 5Homo sapiens (human)
ciliumAdenylate cyclase type 5Homo sapiens (human)
membraneAdenylate cyclase type 5Homo sapiens (human)
plasma membraneAdenylate cyclase type 5Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
ciliumD(1B) dopamine receptorHomo sapiens (human)
brush border membraneD(1B) dopamine receptorHomo sapiens (human)
synapseD(1B) dopamine receptorHomo sapiens (human)
ciliary membraneD(1B) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1B) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
actin cytoskeletonAdenylate cyclase type 8Homo sapiens (human)
plasma membraneAdenylate cyclase type 8Homo sapiens (human)
caveolaAdenylate cyclase type 8Homo sapiens (human)
clathrin-coated pitAdenylate cyclase type 8Homo sapiens (human)
postsynaptic densityAdenylate cyclase type 8Homo sapiens (human)
membraneAdenylate cyclase type 8Homo sapiens (human)
basolateral plasma membraneAdenylate cyclase type 8Homo sapiens (human)
apical plasma membraneAdenylate cyclase type 8Homo sapiens (human)
axonAdenylate cyclase type 8Homo sapiens (human)
dendriteAdenylate cyclase type 8Homo sapiens (human)
clathrin-coated vesicle membraneAdenylate cyclase type 8Homo sapiens (human)
neuronal cell body membraneAdenylate cyclase type 8Homo sapiens (human)
presynaptic membraneAdenylate cyclase type 8Homo sapiens (human)
plasma membrane raftAdenylate cyclase type 8Homo sapiens (human)
membrane raftAdenylate cyclase type 8Homo sapiens (human)
presynaptic active zoneAdenylate cyclase type 8Homo sapiens (human)
excitatory synapseAdenylate cyclase type 8Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenylate cyclase type 8Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseAdenylate cyclase type 8Homo sapiens (human)
glutamatergic synapseAdenylate cyclase type 8Homo sapiens (human)
plasma membraneAdenylate cyclase type 8Homo sapiens (human)
plasma membraneAdenylate cyclase type 7Homo sapiens (human)
membraneAdenylate cyclase type 7Homo sapiens (human)
plasma membraneAdenylate cyclase type 7Homo sapiens (human)
cytoplasmAdenylate cyclase type 2Homo sapiens (human)
plasma membraneAdenylate cyclase type 2Homo sapiens (human)
membraneAdenylate cyclase type 2Homo sapiens (human)
dendriteAdenylate cyclase type 2Homo sapiens (human)
membrane raftAdenylate cyclase type 2Homo sapiens (human)
plasma membraneAdenylate cyclase type 2Homo sapiens (human)
cytoplasmAdenylate cyclase type 1Homo sapiens (human)
plasma membraneAdenylate cyclase type 1Homo sapiens (human)
membrane raftAdenylate cyclase type 1Homo sapiens (human)
extracellular exosomeAdenylate cyclase type 1Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenylate cyclase type 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseAdenylate cyclase type 1Homo sapiens (human)
presynapseAdenylate cyclase type 1Homo sapiens (human)
postsynaptic density membraneAdenylate cyclase type 1Homo sapiens (human)
glutamatergic synapseAdenylate cyclase type 1Homo sapiens (human)
plasma membraneAdenylate cyclase type 1Homo sapiens (human)
cytoplasmAdenylate cyclase type 4Homo sapiens (human)
plasma membraneAdenylate cyclase type 4Homo sapiens (human)
membraneAdenylate cyclase type 4Homo sapiens (human)
dendriteAdenylate cyclase type 4Homo sapiens (human)
plasma membraneAdenylate cyclase type 4Homo sapiens (human)
endoplasmic reticulum membraneDBos taurus (cattle)
dendritic spineDBos taurus (cattle)
ciliary membraneDBos taurus (cattle)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (171)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID61651The compound was tested for binding affinity against Dopamine receptor D1 from rat striatal membranes, using [3H]-SCH- 23390 as radioligand.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
(+/-)-(N-alkylamino)benzazepine analogs: novel dopamine D1 receptor antagonists.
AID55432Half life of recovery for dopamine transporter by D1 receptor in nucleus accumbens was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID1542812Antagonist activity at D1 receptor (unknown origin) expressed in CHOK1 cells assessed as inhibition of SKF38393-induced cAMP accumulation measured after 30 mins2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.
AID145042relative affinity against N-methyl-D-aspartate glutamate receptor in caudate using [3H](+)-MK-801 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID63999Binding potency of compound for Dopamine receptor D2 by displacement of [3H]spiperone1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.
AID187178Inhibition constant of compound on R-(+)-125[I]-8 radioligand binding to rat striatal membranes1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and resolution of (+-)-7-chloro-8-hydroxy-1-(3'-iodophenyl)-3-methyl-2,3,4,5-tetrahydro- 1H-3- benzazepine (TISCH): a high affinity and selective iodinated ligand for CNS D1 dopamine receptor.
AID343747Displacement of [3H]8-OH-DPAT from rat 5HT1A receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
AID1547946Antagonist activity at C-terminal RLuc8-fused D1R (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazi2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID151458relative affinity against Opioid receptor mu 1 in thalamus using [3H]DAMGO as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID346412Displacement of radiolabeled SCH 23390 from human dopamine D1 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID272393Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striata homogenate2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
AID673216Antagonist activity at dopamine D1 receptor assessed as inhibition of [35S]GTPgammaS binding in cell-based assay2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
AID673217Antagonist activity at dopamine D1 receptor assessed as inhibition of [35S]GTPgammaS binding in cell-based assay relative to control2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
AID1547950Antagonist activity at D1R (unknown origin) transfected in human HEK293T cells assessed as increase in cAMP accumulation incubated for 2 hrs by cAMP Glo-sensor assay2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID65881Inhibitory constant against binding of [125I]- IBZM to rat striatal membrane1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide.
AID61197Binding affinity against Dopamine receptor D1 by using [3H]SCH-23390 as radioligand1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands.
AID61658Degradation rate constant for dopamine transporter by D1 receptor in striatum was determined; no significant change2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID61513Binding affinity for dopamine receptor D11991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
AID61526In vitro binding affinity towards Dopamine receptor D1 by displacing [125I]FISCH radioligand in rat striatal homogenate1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
(+/-)-7-chloro-8-hydroxy-1-(4'-[125I]iodophenyl)-3-methyl-2,3,4,5- tetrahydro-1H-3-benzazepine: a potential CNS D-1 dopamine receptor imaging agent.
AID64624relative affinity against Dopamine receptor D2 in striatum using [3H]YM-09151-2 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID343743Displacement of [3H]SCH-23390 from human dopamine D1 receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
AID63051Ability to inhibit the dopamine-stimulated adenylate-cyclase activity in dispersed cells of bovine parathyroid gland1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Development of a high affinity and stereoselective photoaffinity label for the D-1 dopamine receptor: synthesis and resolution of 7-[125I]iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro- 1H-3-benzazepine.
AID61347Binding affinity of compound towards dopamine receptor D1 was determined in rat striatal homogenate using [3H]SCH-23390 as radioligand1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
AID458496Binding affinity to dopamine D1 receptor2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists.
AID61830Binding potency of compound for Dopamine receptor D1 by displacing [3H]SCH-23390 radioligand1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.
AID233506DSAC inhibitory potency obtained by the conversion of [32P]-ATP to [32P]-cAMP1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.
AID751752Displacement of [3H]SCH23390 from human recombinant dopamine D1 receptor expressed in CHO cells at 10 uM after 2 hrs relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID673218Agonist activity at dopamine D1 receptor assessed as [35S]GTPgammaS binding in cell-based assay2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
AID63207Ability to inhibit [3H]-SCH- 23390 binding to Dopamine receptor D1 of canine striatal membranes1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Development of a high affinity and stereoselective photoaffinity label for the D-1 dopamine receptor: synthesis and resolution of 7-[125I]iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro- 1H-3-benzazepine.
AID343746Displacement of [3H]8-OH-DPAT from rat 5HT1A receptor expressed in CHO cells at 10 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
AID61669Binding Affinity was determined against Dopamine receptor D1 in rat striatal membranes using [3H]- SCH 23390 radioligand.2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Binding and preliminary evaluation of 5-hydroxy- and 10-hydroxy-2,3, 12,12a-tetrahydro-1H-[1]benzoxepino[2,3,4-ij]isoquinolines as dopamine receptor ligands.
AID61822Binding affinity to displace [3H]- SCH 23390 against Dopamine receptor D11990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.
AID343745Displacement of [3H]spiperone from human dopamine D2 receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
AID55431Degradation rate constant for dopamine transporter by D1 receptor in nucleus accumbens was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID63050Ability to inhibit [3H]-SCH- 23390 binding to Dopamine receptor D1 of calf parathyroid gland1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Development of a high affinity and stereoselective photoaffinity label for the D-1 dopamine receptor: synthesis and resolution of 7-[125I]iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro- 1H-3-benzazepine.
AID187137In vitro binding affinity to the rat striatal homogenate.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
(+/-)-7-chloro-8-hydroxy-1-(4'-[125I]iodophenyl)-3-methyl-2,3,4,5- tetrahydro-1H-3-benzazepine: a potential CNS D-1 dopamine receptor imaging agent.
AID673208Displacement of [3H]SCH23390 from human dopamine D1 receptor expressed in HEK293 cells2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
AID673219Agonist activity at dopamine D1 receptor assessed as [35S]GTPgammaS binding in cell-based assay relative to control2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
AID1409499Antagonist activity at dopamine D2 receptor long isoform (unknown origin) expressed in HEK293 cells assessed as inhibition of dopamine-induced calcium flux at 10 uM after 15 mins by calcium 4-dye based FLIPR assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
AID61201Relative affinity for Dopamine receptor D1 in striatum using [3H]SCH-233901998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID61843Binding affinity to displace [3H]- SCH 23390 against Dopamine receptor D11990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.
AID61659Half life of recovery for dopamine transporter by Dopamine receptor D1 in striatum was determined; no significant change2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID1242914Displacement of [3H]-SCH-23390 from dopamine D1 receptor (unknown origin) expressed in HEK293 cell membranes incubated for 15 mins by liquid scintillation spectrometry2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.
AID762433Inhibition of GIRK (unknown origin)2013Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16
Discovery of 'molecular switches' within a GIRK activator scaffold that afford selective GIRK inhibitors.
AID272395Intrinsic activity at human dopamine D1 receptor expressed in HEK293 cells assessed as stimulation of cAMP production relative to dopamine2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
AID5730Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
Cyclopentadienyltricarbonylrheniumbenzazepines: synthesis and binding affinity.
AID64424In vitro binding affinity towards rat Dopamine receptor D2 by [3H]spiperone displacement.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Aporphines as antagonists of dopamine D-1 receptors.
AID238595In vitro binding affinity for Alpha-2a adrenergic receptor2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
AID226638Hill coefficient value.1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.
AID252340Amount of cGMP in rat neostriatal membranes after incubation at 10 uM2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists.
AID61181In vitro binding affinity towards rat Dopamine receptor D1 by [3H]SCH-23390 displacement.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Aporphines as antagonists of dopamine D-1 receptors.
AID61349Binding affinity for dopamine receptor D1 in rat striatal homogenate1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.
AID238434In vitro binding affinity for Dopamine receptor D22005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
AID340241Inhibition of human dopamine D1 receptor2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID34315Stimulation of Adenylate cyclase from rat striatal membranes1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
AID88009Displacement of [3H](-)-trans-H2-PAT from histamine H2 PAT binding site by competition binding assay.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID233819Relative binding affinity for dopamine receptors D1 and D2 in rat striatal homogenates1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.
AID182827In vitro inhibition of adenylate cyclase stimulation caused by 10 uM dopamine in rat retinal tissue by 0.1 uM.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Aporphines as antagonists of dopamine D-1 receptors.
AID343744Displacement of [3H]spiperone from human dopamine D2 receptor expressed in HEK293 cells at 10 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
AID1409500Antagonist activity at dopamine D2 receptor long isoform (unknown origin) expressed in HEK293 cells assessed as inhibition of dopamine-induced calcium flux after 15 mins by calcium 4-dye based FLIPR assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
AID61377Binding affinity towards dopamine receptor D1 using [3H]SCH-23390 was determined in rat striatal membranes1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.
AID458498Binding affinity to dopamine D2 receptor2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists.
AID272396Activity at rat dopamine D2L receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
AID34444Inhibition of dopamine sensitive adenylate cyclase at 0.01 uM1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Evaluation of isomeric 4-(chlorohydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines as dopamine D-1 antagonists.
AID61498Binding affinity towards Dopamine receptor D11987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID61509Binding affinity at Dopamine receptor D1 in rat neostriatum by [3H]-SCH- 23390 displacement.1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Synthesis, resolution, and preliminary evaluation of trans-2-amino-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes and related derivatives as dopamine receptors ligands.
AID65718In vitro affinity of compound towards Dopamine receptor D2 was determined by measuring their ability to displace [3H]spiperone from rat striatal homogenates1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1H-3-benzazepin-7-ol.
AID63803Binding affinity against dopamine (D2) receptor1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.
AID203852The compound was tested for affinity towards sigma-3 receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.
AID233664Selectivity ratio of binding affinity towards dopamine D2 and D1 receptors1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands.
AID61666Degradation rate constant for dopamine transporter by D1 receptor in nucleus accumbens was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID272399Intrinsic activity at human dopamine D4.4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production relative to dopamine2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
AID1547947Antagonist activity at C-terminal RLuc8-fused D1R (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazi2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID34465Activity was determined against Adenylate cyclase1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Aporphines as antagonists of dopamine D-1 receptors.
AID65590relative affinity against Dopamine receptor D3 in ventral striatum using [3H](+)-7-OH-DPAT as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID64630Binding affinity towards dopamine receptor D2 at 1.0 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID272397Intrinsic activity at rat dopamine D2L receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production relative to dopamine2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
AID502876Displacement of [3H]SCH23390 from D1 like receptor in pig striatal tissue by topcount scintillation counting2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists.
AID218671Binding affinity towards alpha-1 adrenergic receptor at 1.0 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID64786The compound is evaluated for the affinity towards Dopamine receptor D2, using [3H]-spiperone as ligand on rat striatal membranes; not applicable1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine.
AID346416Displacement of radiolabeled SCH-23390 from human dopamine D5 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID61196Tested for its affinity towards Dopamine receptor D1 in rat striatal membrane1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
AID237878Oral bioavailability in rat at 24 hr (dose 10 mg/kg)2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
AID5241Binding affinity towards 5-hydroxytryptamine 2 receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID65257Inhibition of [3H]spiperone binding to Dopamine receptor D2 at 0.02 nM1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands.
AID611929Displacement of [3H]SCH23390 from human dopamine D1 receptor2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
AID204392relative affinity against serotonin transporter using RTI-55 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID236455Area under the concentration curve from 0 to 6 hr in rat after oral administration at 10 mg/kg dosage2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
AID238356In vitro binding affinity for 5-HT transporter2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
AID65092Binding affinity at Dopamine receptor D2 in rat striatal homogenate by [3H]-spiperone displacement.1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Synthesis, resolution, and preliminary evaluation of trans-2-amino-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes and related derivatives as dopamine receptors ligands.
AID61343Inhibition of [3H]SCH-23390 binding to rat striatal membrane Dopamine receptor D11999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane.
AID233473Hill slope was determined for the compound in D1 receptor binding assay1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
AID238433In vitro binding affinity for Dopamine receptor D12005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
AID34445Inhibition of dopamine sensitive adenylate cyclase at 0.1 uM1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Evaluation of isomeric 4-(chlorohydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines as dopamine D-1 antagonists.
AID63822In vitro ability to displace [3H]spiperone binding from dopamine receptor D2 in rat striatal membrane.1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical an
AID34446Inhibition of dopamine sensitive adenylate cyclase at 1 uM1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Evaluation of isomeric 4-(chlorohydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines as dopamine D-1 antagonists.
AID458497Binding affinity to dopamine D5 receptor2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists.
AID65827Inhibition of dopamine-stimulated adenylate cyclase obtained from rat corpus striatum was determined by the conversion of [32P]ATP to [32P]-cAMP1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands.
AID64782Binding affinity of compound towards Dopamine receptor D2 was determined in rat striatal homogenate using [3H]- spiperone as radioligand; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
AID64300Compound was evaluated for affinity towards dopamine D2-like receptor in homogenate of caudate putamen tissue from rat brain2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
Cyclopentadienyltricarbonylrheniumbenzazepines: synthesis and binding affinity.
AID65159relative affinity against dopamine transporter using WIN-35428 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID61345Affinity towards Dopamine receptor D1 was evaluated in rat striatal membrane using [3H]SCH-23,390 as radioligand1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
AID238435In vitro binding affinity for Dopamine receptor D52005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
AID182828In vitro inhibition of adenylate cyclase stimulation caused by 10 uM dopamine in rat retinal tissue by 10 uM.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Aporphines as antagonists of dopamine D-1 receptors.
AID1664375Antagonist activity at dopamine D5 receptor (unknown origin)2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.
AID252341Amount of cGMP in rat neostriatal membranes after incubation at 0.1 uM2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists.
AID751687Displacement of [3H]SCH23390 from human recombinant dopamine D1 receptor expressed in CHO cells after 2 hrs2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID232210Selectivity for D1 receptor was determined as the ratio of Ki (D2) to that of Ki (D1)1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.
AID61673Binding affinity against dopamine receptor D11994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.
AID61519In vitro affinity of compound towards dopamine (D1) receptor was determined by measuring their ability to displace [3H]SCH-23,390 from rat striatal homogenates1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1H-3-benzazepin-7-ol.
AID239294Inhibitory constant for [3H]SCH-23390 binding to Dopamine receptor D1-like of porcine striatal membranes2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists.
AID272394Activity at human dopamine D1 receptor expressed in HEK293 cells assessed as stimulation of cAMP production2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
AID61503Inhibition of [3H]SCH-23,390 binding to Dopamine receptor D1 at 0.25 nM1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands.
AID239505Inhibitory constant of compound against [3H]YM-09151-2 binding to Dopamine receptor D2 like in porcine striatal membranes; NT= not tested2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists.
AID203916Binding affinity towards serotonin S1 receptor at 1.0 uM1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID64779Affinity towards Dopamine receptor D2 was evaluated in rat striatal membrane using [3H]spiperone as radioligand1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
AID1664374Antagonist activity at dopamine D1 receptor (unknown origin)2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.
AID566248Inhibition of human dopamine D1 receptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID64195Binding affinity towards dopamine (D1) receptor using [3H]spiperone was determined in rat striatal membranes1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.
AID34316Percentage maximum stimulation adenylate cyclase was measured versus DA1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
AID63206Ability to inhibit the binding of [3H]-SCH- 23390 to canine striatal membrane1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
A photoaffinity label for the D-1 dopamine receptor, (RS)-7-[125I]Iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5- tetrahydro-1H-3-benzazepine, selectively identifies the ligand binding subunits of the receptor.
AID64783Binding affinity for Dopamine receptor D2 of rat striatal homogenate1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.
AID208185Tested effective dose for maximal stimulation of adenylate cyclase in rat striatal membrane; NA= not applicable1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
AID64438Inhibition of 0.1 nM of [125I]- (S)-N-(1-Ethyl-pyrrolidin-2-ylmethyl)-5-iodo-2-methoxy-benzamide binding in striatal homogenates of rat brain1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
(S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[125I]iodo- 2-methoxybenzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors.
AID61353The compound is evaluated for the affinity towards Dopamine receptor D1, using [3H]- SCH 23390 as ligand on rat striatal membranes.1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine.
AID61825Compound was tested for the displacement of [3H]-SCH- 23390 from dopamine receptor D11992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
A study on the contribution of the 1-phenyl substituent to the molecular electrostatic potentials of some benzazepines in relation to selective dopamine D-1 receptor activity.
AID236679Maximum plasma concentration in rat after oral administration at 10 mg/kg dosage2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
AID63370Displacement of [3H]- #NAME? from binding Dopamine receptor D1 in rat striatum1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
AID64282Displacement of [3H]- -spiperone from Dopamine receptor D2 in rat striatum1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
AID65877In vivo compound was evaluated for binding towards Dopamine receptor D2 in rat striatal membranes using competitive binding assay and [125I]IBZM radioligand1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents.
AID63372Affinity towards dopamine receptor D1 in rat corpus striatum tissue.1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods.
AID1547951Antagonist activity at D1R (unknown origin) transfected in human HEK293T cells assessed as increase in cAMP accumulation incubated for 2 hrs by cAMP Glo-sensor assay relative to control2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID65625Tested for binding affinity against dopamine receptor D3 expressed in Sf9 cells.1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.
AID61861Compound was evaluated for affinity towards dopamine D1-like receptor in homogenate of caudate putamen tissue from rat brain2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
Cyclopentadienyltricarbonylrheniumbenzazepines: synthesis and binding affinity.
AID272398Activity at human dopamine D4.4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
AID343742Displacement of [3H]SCH-23390 from human dopamine D1 receptor expressed in HEK293 cells at 10 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
AID255273Percent inhibition against Dopamine receptor D1 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID65429Binding affinity for dopamine receptor D21991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
AID272392Displacement of [3H]SCH-23390 from dopamine D1-like receptor in porcine striata homogenate2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
AID34289In vitro inhibition of dopamine stimulated adenylate cyclase1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
AID447915Ionization constant for the compound (pKa)2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Design and discovery of 1,3-benzodiazepines as novel dopamine antagonists.
AID252342Amount of cGMP in rat neostriatal membranes after incubation at 1.0 uM2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists.
AID5547Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
Cyclopentadienyltricarbonylrheniumbenzazepines: synthesis and binding affinity.
AID148450relative affinity against Opioid receptor kappa 1 in insular Ctx using [3H]U-69593 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID34597Effective concentration against adenylate cyclase; NA= not applicable1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
AID64439Inhibition of [3H](S)-sulpiride binding in striatal homogenates of rat brain1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
(S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[125I]iodo- 2-methoxybenzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors.
AID1542813Antagonist activity at D2 receptor (unknown origin) expressed in CHOK1 cells assessed as inhibition of dopamine-induced calcium flux preincubated for 60 mins at 37 degC followed by 15 mins incubation under room temperature and subsequent dopamine addition2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (787)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (1.14)18.7374
1990's24 (3.05)18.2507
2000's87 (11.05)29.6817
2010's609 (77.38)24.3611
2020's58 (7.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.21 (24.57)
Research Supply Index6.69 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index45.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (0.37%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other800 (99.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]